Clinical Trial

BCMA-CD19 CCAR T Cell Treatment of Refractory Immune Thrombocytopenia Associated with Autoimmune Diseases

Name: BCMA-CD19 CCAR T Cell Treatment of Refractory Immune Thrombocytopenia Associated with Autoimmune Diseases — clinical trial record (NCT06787989)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of BCMA-CD19 cCAR T cells in patients with refractory ITP associated with autoimmune disease.

Trial Details

NCT Number	NCT06787989
Lead Sponsor	iCell Gene Therapeutics Collaborators: iCell ImmunityX（Hangzhou）Co., Ltd.
Conditions	Refractory Immune Cytopenia
Enrollment	20 participants
Start Date	2024-08-31
Primary Completion	2026-08 (estimated)
Study Completion	2027-04 (estimated)
Updated on ClinicalTrials.gov	2025-01-22